Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 319

1.

A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression.

Chakravarthi BVSK, Rodriguez Pena MDC, Agarwal S, Chandrashekar DS, Hodigere Balasubramanya SA, Jabboure FJ, Matoso A, Bivalacqua TJ, Rezaei K, Chaux A, Grizzle WE, Sonpavde G, Gordetsky J, Netto GJ, Varambally S.

Neoplasia. 2018 Sep;20(9):894-904. doi: 10.1016/j.neo.2018.07.006. Epub 2018 Aug 15.

2.

ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.

Monteiro LL, Witjes JA, Agarwal PK, Anderson CB, Bivalacqua TJ, Bochner BH, Boormans JL, Chang SS, Domínguez-Escrig JL, McKiernan JM, Dinney C, Godoy G, Kulkarni GS, Mariappan P, O'Donnell MA, Rentsch CA, Shah JB, Solsona E, Svatek RS, van der Heijden AG, van Valenberg FJP, Kassouf W.

World J Urol. 2018 Aug 14. doi: 10.1007/s00345-018-2438-9. [Epub ahead of print] Review.

PMID:
30109483
3.

Characterization of voiding function and structural bladder changes in a rat model of neurogenic underactive bladder disease.

Weyne E, Dewulf K, Deruyer Y, Rietjens R, Everaerts W, Bivalacqua TJ, De Ridder D, Van der Aa F, Albersen M.

Neurourol Urodyn. 2018 Jun;37(5):1594-1604. doi: 10.1002/nau.23517. Epub 2018 Feb 7.

PMID:
30105760
4.

Editorial Comment.

Kates M, Bivalacqua TJ.

J Urol. 2018 Jul 28. pii: S0022-5347(18)43600-2. doi: 10.1016/j.juro.2018.05.157. [Epub ahead of print] No abstract available.

PMID:
30063891
5.

Hospitalisation and readmission costs after radical cystectomy in a nationally representative sample: does urinary reconstruction matter?

Joice GA, Chappidi MR, Patel HD, Kates M, Sopko NA, Stimson CJ, Pierorazio PM, Bivalacqua TJ.

BJU Int. 2018 Jun 13. doi: 10.1111/bju.14448. [Epub ahead of print]

PMID:
29897156
6.

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.

Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC.

World J Urol. 2018 Jun 7. doi: 10.1007/s00345-018-2361-0. [Epub ahead of print]

PMID:
29882105
7.

Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry.

Daneshmand S, Bazargani ST, Bivalacqua TJ, Holzbeierlein JM, Willard B, Taylor JM, Liao JC, Pohar K, Tierney J, Konety B; Blue Light Cystoscopy with Cysview Registry Group.

Urol Oncol. 2018 Aug;36(8):361.e1-361.e6. doi: 10.1016/j.urolonc.2018.04.013. Epub 2018 May 30.

8.

Organoid culture of bladder cancer cells.

Yoshida T, Singh AK, Bishai WR, McConkey DJ, Bivalacqua TJ.

Investig Clin Urol. 2018 May;59(3):149-151. doi: 10.4111/icu.2018.59.3.149. Epub 2018 Apr 30. No abstract available.

9.

Tissue-Engineered Neo-Urinary Conduit from Decellularized Trachea.

Singh A, Lee D, Jeong H, Yu C, Li J, Fang CH, Sabnekar P, Liu X, Yoshida T, Sopko N, Bivalacqua TJ.

Tissue Eng Part A. 2018 Jun 4. doi: 10.1089/ten.TEA.2017.0436. [Epub ahead of print]

PMID:
29649957
10.

Urinary cytology and the Paris system for reporting urinary cytology: Implications for urological management.

Gupta M, VandenBussche CJ, Bivalacqua TJ.

Cytopathology. 2018 Aug;29(4):368-370. doi: 10.1111/cyt.12538. Epub 2018 Mar 25.

PMID:
29575439
11.

Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.

Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, Cohen JD, Taheri D, Silliman N, Schaefer J, Ptak J, Dobbyn L, Papoli M, Kinde I, Afsari B, Tregnago AC, Bezerra SM, VandenBussche C, Fujita K, Ertoy D, Cunha IW, Yu L, Bivalacqua TJ, Grollman AP, Diaz LA, Karchin R, Danilova L, Huang CY, Shun CT, Turesky RJ, Yun BH, Rosenquist TA, Pu YS, Hruban RH, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Dickman KG, Netto GJ.

Elife. 2018 Mar 20;7. pii: e32143. doi: 10.7554/eLife.32143.

12.

Galanin Administration Partially Restores Erectile Function After Cavernous Nerve Injury and Mediates Endogenous Nitrergic Nerve Outgrowth In Vitro.

Weyne E, Hannan JL, Gevaert T, Soebadi MA, Matsui H, Castiglione F, van Renterghem K, De Ridder D, Van der Aa F, Bivalacqua TJ, Albersen M.

J Sex Med. 2018 Apr;15(4):480-491. doi: 10.1016/j.jsxm.2018.02.013. Epub 2018 Mar 14.

PMID:
29550465
13.

Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells.

Yoshida T, Sopko NA, Kates M, Liu X, Joice G, McConkey DJ, Bivalacqua TJ.

Oncotarget. 2018 Jan 24;9(13):11060-11070. doi: 10.18632/oncotarget.24308. eCollection 2018 Feb 16.

14.

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.

Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM.

Urol Oncol. 2018 Feb 26. pii: S1078-1439(18)30036-X. doi: 10.1016/j.urolonc.2018.01.014. [Epub ahead of print] Review.

PMID:
29496372
15.

Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.

Chalfin HJ, Kates M, van der Toom EE, Glavaris S, Verdone JE, Hahn NM, Pienta KJ, Bivalacqua TJ, Gorin MA.

Urology. 2018 May;115:82-86. doi: 10.1016/j.urology.2018.01.036. Epub 2018 Feb 9.

PMID:
29432873
16.

Molecular Profile of Priapism Associated with Low Nitric Oxide Bioavailability.

La Favor JD, Fu Z, Venkatraman V, Bivalacqua TJ, Van Eyk JE, Burnett AL.

J Proteome Res. 2018 Mar 2;17(3):1031-1040. doi: 10.1021/acs.jproteome.7b00657. Epub 2018 Feb 12.

PMID:
29394072
17.

Surgical Factors Associated With Male and Female Sexual Dysfunction After Radical Cystectomy: What Do We Know and How Can We Improve Outcomes?

Pederzoli F, Campbell JD, Matsui H, Sopko NA, Bivalacqua TJ.

Sex Med Rev. 2018 Jul;6(3):469-481. doi: 10.1016/j.sxmr.2017.11.003. Epub 2018 Jan 19. Review.

PMID:
29371143
18.

Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.

Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W; Collaborators.

J Urol. 2018 Jun;199(6):1452-1458. doi: 10.1016/j.juro.2017.12.062. Epub 2018 Jan 9.

PMID:
29329894
19.

Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.

Liao RS, Gupta M, Schwen ZR, Patel HD, Kates M, Johnson MH, Hahn NM, McConkey D, Bivalacqua TJ, Pierorazio PM.

J Urol. 2018 Jul;200(1):68-73. doi: 10.1016/j.juro.2017.12.054. Epub 2018 Jan 4.

PMID:
29307680
20.

Ex vivo culture of tumor cells from N-methyl-N-nitrosourea-induced bladder cancer in rats: Development of organoids and an immortalized cell line.

Yoshida T, Kates M, Sopko NA, Liu X, Singh AK, Bishai WR, Joice G, McConkey DJ, Bivalacqua TJ.

Urol Oncol. 2018 Apr;36(4):160.e23-160.e32. doi: 10.1016/j.urolonc.2017.11.024. Epub 2017 Dec 26.

PMID:
29288005

Supplemental Content

Loading ...
Support Center